Management of Granulomatous Cystitis with Irritative Voiding Symptoms After BCG Therapy

Diagnostic Assessment

The American Urological Association recommends performing a urine culture to rule out concurrent bacterial infection before proceeding with treatment 1, 4
Evaluate the severity and duration of symptoms to determine appropriate management strategy 2
Consider cystoscopy to assess the extent of granulomatous changes if not recently performed, as suggested by the National Comprehensive Cancer Network 5

Immediately suspend BCG instillations to prevent worsening of granulomatous inflammation, as recommended by the Military Medical Research 1, 3
Initiate anti-tuberculosis therapy with isoniazid and rifampicin for three months, plus quinolone antibiotics and corticosteroids, according to the Military Medical Research guidelines 1, 2, 3
Add quinolone antibiotics to address potential bacterial component 1, 2
Include corticosteroids to reduce inflammation 1, 3

Continue oxybutynin for bladder spasms and irritative symptoms, as suggested by Praxis Medical Insights 6
Maintain pyridium for symptomatic relief of pain and discomfort 6
Consider adding NSAIDs for additional anti-inflammatory effect 6

If symptoms persist despite treatment, consider intravesical instillation therapy with quinolones and anti-inflammatory drugs once daily for 5 days, as recommended by the Military Medical Research 1, 2
Lidocaine instillations may be used for pain relief if severe bladder spasms continue 3
Regular cystoscopic surveillance at 3-6 month intervals to monitor disease progression is recommended by the National Comprehensive Cancer Network and Praxis Medical Insights 5, 6

Monitor for bladder contracture, which may develop in severe cases of granulomatous cystitis, as warned by the Military Medical Research 3
Watch for systemic spread of BCG infection, which would require more aggressive anti-tuberculosis therapy, according to the Military Medical Research 2
Be alert for signs of upper tract involvement that may require imaging, as suggested by the National Comprehensive Cancer Network and Praxis Medical Insights 5, 6

Avoid resuming BCG therapy until complete resolution of granulomatous cystitis, as recommended by the Military Medical Research 2
Consider alternative intravesical agents for bladder cancer management if BCG cannot be resumed, according to the Military Medical Research 7, 8

Granulomatous cystitis is a known complication of BCG therapy that requires prompt intervention to prevent progression to bladder contracture, as noted by the Military Medical Research 1
Current symptomatic treatment with oxybutynin and pyridium alone is insufficient for managing granulomatous inflammation, as stated by the Military Medical Research and Praxis Medical Insights 1, 6
Regular follow-up is essential to monitor treatment response and detect potential complications early, as recommended by the National Comprehensive Cancer Network and Praxis Medical Insights 5, 6